ArticlePsoriasis (Auckland, N.Z.)2022

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study.

Matteo Megna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.